Drug intelligence / Profile preview

BBP-472

Development stage: Unknown
Lead developer: BridgeBio Pharma
Modality: Small Molecules

Overview

BBP-472 is an investigational **small molecule** inhibitor of phosphatidylinositol 3-kinase beta designed to selectively inhibit the PI3K beta isoform within the PI3K signaling pathway. It was initially developed by BridgeBio Pharma. Publicly available information indicates that the program was discontinued, and specific clinical indications, dosage form, route of administration, and any marketed brand name have not been clearly established from the provided evidence.

Targets

PIK3CB (Phosphatidylinositol 3-kinase beta subunit)

Beyond the preview

Go deeper on BBP-472.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBP-472.

Explore the full profile